5 terminated. 5 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Terminated 5 |
| Phase 3 | 2 | Terminated 2 |
| Phase 1 | 1 | Terminated 1 |
Follow Cerebrovascular Accident: new trials by email Literature Review of Cerebrovascular Accident trials Research Report on Cerebrovascular Accident
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity Phase 2; Low Dose MYOBLOC (10,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 2; Placebo - Spasticity, Cerebrovascular Accident | Phase 2 / Phase 3 | Terminated | Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC | 32 | 2021-11-02 | 2026-05-27 |
| Proof of Concept (POC) in Patients With Ischaemic Stroke GSK249320 100/mg, Placebo - Cerebrovascular Accident | Phase 2 | Terminated | GlaxoSmithKline | 134 | 2013-05-18 | 2017-11-17 |
| Clinic-Based AMES Treatment of Stroke Assisted movement and enhanced sensation - Stroke, Cerebrovascular Accident | Phase 1 / Phase 2 | Terminated | Oregon Health and Science University | 3 | 2008-04-01 | 2017-01-23 |
| A Study to Evaluate the Effects of ONO-2506 Intravenous Infusion in Patients With Acute Ischemic Stroke ONO-2506 - Cerebrovascular Accident | Phase 2 / Phase 3 | Terminated | Ono Pharma USA Inc | 1320 | 2002-11-01 | 2012-10-11 |
| E-Selectin Nasal Spray to Prevent Stroke Recurrence E-Selectin nasal spray - Cerebrovascular Accident, Transient Ischemic Attack | Phase 2 | Terminated | National Institute of Neurological Disorders and Stroke (NINDS) | 60 | 2001-03-01 | 2010-05-04 |
Stroke (5) · Ischemic Stroke (2) · Brain Injuries, Traumatic (1) · Camurati-Engelmann Syndrome (1) · Cerebral Palsy (1) · Hemiplegia (1) · Ischemic Attack, Transient (1) · Multiple Sclerosis (1) · Muscle Spasticity (1)
Brain Diseases (5) · Cardiovascular Diseases (5) · Central Nervous System Diseases (5) · Cerebrovascular Disorders (5) · Nervous System Diseases (5) · Vascular Diseases (5) · Musculoskeletal Diseases (2) · Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Bone Diseases (1) · Bone Diseases, Developmental (1) · Brain Damage, Chronic (1) · Brain Injuries (1) · Brain Ischemia (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)
Clinical Trials, Phase II as Topic (1) · Clinical Trials, Phase III as Topic (1) · ONO2506 (1) · rimabotulinumtoxinB (1)
GlaxoSmithKline (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1) · Ono Pharma USA Inc (1) · Oregon Health and Science University (1) · Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC (1)
United States (5) · Canada (2) · Germany (1) · Hungary (1) · Poland (1) · United Kingdom (1)
Bryan Due, Ph.D. (1) · Joseph T Hull, PhD (1) · Paul J. Cordo, PhD (1)